Or smell like a rat chaser collecting patients for a backyard company that can't get humans to sign up. That isn't this site though as our CEO has indicated the re submission is this quarter and last time we had 9-1 in favour and since then we have recruited a former top FDA operator and seemingly met the required concerns. Time again will tell, but the FDA losing a recent court case trying to prevent stem cell therapy from evolving has really put a spanner in the works. The sweat shops and cowboys operating stem cell therapy in the USA are moving forward and getting good reviews as the FDA sit on the next big Standard Of Care unable to block it.
MSB Price at posting:
94.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)